Fowler, Nathan Hale http://orcid.org/0000-0002-9494-1877
Chavez, Julio C. http://orcid.org/0000-0002-2045-6238
Riedell, Peter A. http://orcid.org/0000-0003-2719-0580
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Accepted: 6 May 2024
First Online: 19 June 2024
Change Date: 19 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11523-024-01085-6
Declarations
:
: Financial support for medical writing was provided by Novartis Pharmaceuticals Corporation. Novartis had no role in the content development or manuscript writing and revisions.
: Nathan Hale Fowler reports receiving grants or contracts from Novartis and TG Therapeutics and participation on a data safety monitoring board or advisory board for Gilead, BMS, and Roche. Julio C. Chavez reports a consulting/advisory role for Kite Pharma/Gilead, Novartis, Bayer, Karyopharm Therapeutics, Verastem, Pfizer, MorphoSys, TeneoBio, Juno Therapeutics, and Celgene; speaker’s bureau participation with Kite Pharma/Gilead, Genentech, AstraZeneca, and BeiGene; and research funding to the institute from Merck. Peter A. Riedell reports consulting for Novartis, BeiGene, and Celgene/BMS; research funding from Kite Pharma/Gilead, Novartis, Celgene/BMS, Calibr, Xencor, Tessa Therapeutics, and MorphoSys; receiving honoraria from Novartis; speaker’s bureau participation with Kite Pharma/Gilead; and membership as a board of directors or advisory committee for Novartis, Takeda, Janssen, Celgene/BMS, Bayer, and Karyopharm Therapeutics.
: Not applicable.
: Not applicable.
: Not applicable.
: The data supporting the conclusion of this study have been included within the article.
: Not applicable.
: All authors interpreted the data, made substantial revisions to manuscript drafts for important intellectual content, and approved the final version.